Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4.
Por:
Kayser S, Martínez-Cuadrón D, Hanoun M, Stölzel F, Gil C, Reinhardt HC, Aguiar E, Schäfer-Eckart K, Burgues JMB, Steffen B, Bernal T, Krause SW, Riaza R, Schliemann C, Cervera J, Kaufmann M, Torres-Miñana L, Hänel M, Acuña-Cruz E, Jost E, Algarra JL, Crysandt M, Fransecky L, Cornago-Navascues J, Kraus S, Martinez-Lopez J, Einsele H, Niemann D, Neubauer A, Seggewiß-Bernhardt R, Scholl S, Klein SA, Schmid C, Schaich M, Schmidt-Hieber M, Zukunft S, Ho AD, Platzbecker U, Baldus CD, Müller-Tidow C, Thiede C, Bornhäuser M, Serve H, Levis M, Montesinos P, Röllig C and Schlenk RF
Publicada:
1 ene 2023
Ahead of Print:
9 jun 2022
Resumen:
We retrospectively studied 125 AML patients with trisomy 4 (median age at diagnosis, 58 years; range, 16-77 years) treated between 2000 and 2019 within a multicenter study. Trisomy 4 was the sole abnormality in 28 (22%) patients and additional abnormalities were present in 97 (78%) patients. Twenty-two (22%) and 15 (15%) of 101 tested patients harbored NPM1 and FLT3-ITD mutations. Two (3%) of 72 tested patients were CEBPA double mutated. Data on response to intensive anthracycline-based induction therapy were available in 119 patients. Complete remission (CR) was achieved in 67% (n=80) and early death rate was 5% (n=6). Notably, patients with trisomy 4 as sole abnormality had a CR rate of 89%. An allo-HCT was performed in 40 (34%) patients, of whom 19 patients were transplanted in CR1. Median follow-up of the intensively treated cohort was 5.76 years (95%-CI, 2.99-7.61 years). Five-year overall survival (OS) and relapse-free survival were 30% (95%-CI, 22-41%) and 27% (95%-CI, 18-41%). An Andersen-Gill regression model on OS revealed ELN favorable-risk (HR, 0.34; P=0.006) and trisomy 4 as sole abnormality (HR, 0.41 P=0.01) as favorable factors, whereas age with a difference of ten years (HR, 1.15, P=0.11), female gender (OR, 0.74; P=0.20) and allo-HCT (OR, 0.64; P=0.14) had no significant impact. In our cohort, patients with trisomy 4 as a sole abnormality had a high CR rate and favorable clinical outcome. Allo-HCT seems not to improve OS.
Filiaciones:
Kayser S:
Medical Clinic and Policlinic I, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany
NCT Trial Center, National Center of Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg.
Martínez-Cuadrón D:
Hematology Department, Hospital Universitari i Politècnic, La Fe, València, Spain
CIBERONC, Instituto Carlos III, Madrid
Hanoun M:
Department of Hematology and Stem Cell Transplantation, University Hospital Essen
Stölzel F:
Department of Medicine I, University Hospital Carl-Gustav-Carus, Dresden
:
Hospital General, Alicante
Reinhardt HC:
Department of Hematology and Stem Cell Transplantation, University Hospital Essen
Aguiar E:
Clinical Haematology Department, Centro Hospitalar São João, Oporto
Schäfer-Eckart K:
Hospital Nord, Nurnberg
Burgues JMB:
Hematology Department, Hospital San Pedro Acantara, Cáceres
Steffen B:
Department of Internal Medicine II, University Hospital of Frankfurt Main
Bernal T:
Hospital Central de Asturias, Oviedo
Krause SW:
Department of Internal Medicine 5 - Hematology/Oncology, University Hospital of Erlangen
Riaza R:
Hematology Department, Hospital Universitario Severo Ochoa, Madrid
Schliemann C:
University Hospital Muenster, Muenster
Cervera J:
Hematology Department, Hospital Universitari i Politècnic, La Fe, València, Spain
CIBERONC, Instituto Carlos III, Madrid
Kaufmann M:
Robert Bosch Hospital Stuttgart, Stuttgart
Torres-Miñana L:
Hematology Department, Hospital Universitari i Politècnic, La Fe, València, Spain
CIBERONC, Instituto Carlos III, Madrid
Hänel M:
Klinikum Chemnitz, Chemnitz
Acuña-Cruz E:
Hematology Department, Hospital Universitari i Politècnic, La Fe, València, Spain
CIBERONC, Instituto Carlos III, Madrid
Jost E:
Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, University Hospital RWTH Aachen, Aachen
Algarra JL:
Hospital General de Albacete
Crysandt M:
Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, University Hospital RWTH Aachen, Aachen
Fransecky L:
Department of Internal Medicine II, University Hospital of Kiel
Cornago-Navascues J:
Fundación Jiménez Díaz, Madrid
Kraus S:
Universitätsklinikum Würzburg, Würzburg
Martinez-Lopez J:
Hospital 12 de Octubre, Complutense University, CNIO, Madrid
Einsele H:
Universitätsklinikum Würzburg, Würzburg
Niemann D:
Gemeinschaftsklinikum Mittelrhein gGmbH, Koblenz
Neubauer A:
Philipps University Marburg, and University Hospital Giessen and Marburg, Marburg
Seggewiß-Bernhardt R:
Medizinische Klinik V, Sozialstiftung Bamberg, Bamberg
Scholl S:
Friedrich Schiller University, Jena
Klein SA:
Medical Clinic III, University Medicine Mannheim, Mannheim
Schmid C:
Department of Hematology and Oncology, Augsburg University Hospital, Augsburg
Schaich M:
Rems-Murr-Klinikum Winnenden, Winnenden
Schmidt-Hieber M:
Department of Hematology and Oncology, Carl-Thiem-Klinikum, Cottbus, Cottbus
Zukunft S:
Department of Medicine I, University Hospital Carl-Gustav-Carus, Dresden
Ho AD:
Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg
Platzbecker U:
Medical Clinic and Policlinic I, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig
Baldus CD:
Department of Internal Medicine II, University Hospital of Kiel
Müller-Tidow C:
Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg
Thiede C:
Department of Medicine I, University Hospital Carl-Gustav-Carus, Dresden
Bornhäuser M:
Department of Medicine I, University Hospital Carl-Gustav-Carus, Dresden
Serve H:
Department of Internal Medicine II, University Hospital of Frankfurt Main
Levis M:
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
Montesinos P:
Hematology Department, Hospital Universitari i Politècnic, La Fe, València, Spain
CIBERONC, Instituto Carlos III, Madrid
Röllig C:
Department of Medicine I, University Hospital Carl-Gustav-Carus, Dresden
Schlenk RF:
NCT Trial Center, National Center of Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg, Germany
Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg
gold, Green Published
|